Adaptimmune Therapeutics Plc
(NASDAQ) ADAP
Adaptimmune Therapeutics Plc Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$65.09M
Net Income (TTM)
-$169.76M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Estimated Earnings Date
Nov 12, 2025
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Estimated Earnings Date
Nov 12, 2025
ADAP News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Adaptimmune Therapeutics Plc
Industry
Biotechnology
Sector
Health CareEmployees
506
CEO
Adrian Rawcliffe
Website
www.adaptimmune.comHeadquarters
Abingdon, OX14 4RX, GB
ADAP Financials
Key Financial Metrics (TTM)
Gross Margin
83.88%
Operating Margin
-362.66%
Net Income Margin
-371.74%
Return on Equity
143.79%
Return on Capital
-79.90%
Return on Assets
-59.65%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$61.71M
Operating Income
-$164.22M
EBITDA
-$149.75M
Operating Cash Flow
-$190.03M
Capital Expenditure
-$2.89M
Free Cash Flow
-$191.71M
Cash & ST Invst.
$26.06M
Total Debt
$48.68M
Adaptimmune Therapeutics Plc Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$13.68M
-89.3%
Gross Profit
$11.18M
-91.1%
Gross Margin
81.71%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
506
N/A
Net Income
-$30.34M
-143.6%
EBITDA
-$26.26M
-137.0%
Quarterly Fundamentals
Total Cash
$26.06M
-87.9%
Total Debt
$48.68M
+2.8%
Accounts Receivable
$28.90M
+21.6%
Inventory
$11.41M
N/A
Long Term Debt
$44.17M
+5.0%
Short Term Debt
$9.03M
-14.7%
Return on Assets
-59.65%
N/A
Return on Invested Capital
-96.08%
N/A
Free Cash Flow
-$34.86M
-174.7%
Operating Cash Flow
-$34.78M
-173.4%